I’m telling you guys this is the APPLE of robotic surgery. The king of robotic surgery with its da Vinci system, and the new FDA-cleared da Vinci 5 keeps it ahead of the game with cutting-edge precision. The company’s killing it—18% more procedures and a 25% revenue spike to $2.41B in Q4 2024, plus a 15% jump in installed systems to 9,902 globally. They rake in steady cash from instruments and services (part of their $8.4B 2024 revenue, up 17%), and with the surgical robotics market set to hit $7.4B by 2030, ISRG’s poised to ride that wave. Add in AI innovations, a knack for beating earnings (6.78% average surprise), and 13-16% growth projected for 2025, and you’ve got a solid play. Sure, its P/E is steep at 95, but for long-term growth in healthcare tech, this $210B giant’s hard to beat, Thoughts?